Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
66.77 USD | +5.73% |
|
+4.25% | -18.21% |
03:52pm | Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial | DJ |
02:51pm | Gilead's long-acting HIV drug superior to daily pill Truvada in study | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.21% | 78.68B | |
+53.92% | 803B | |
-7.14% | 351B | |
+17.72% | 324B | |
+10.51% | 303B | |
+16.47% | 243B | |
+2.29% | 228B | |
+10.31% | 217B | |
+6.23% | 164B | |
-3.93% | 155B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial